We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,500
Open access books available

135,000
International authors and editors

165M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Interactions of STAP-2 with BRK and STAT3/5 in Breast Cancer Cells

Osamu Ikeda, Yuichi Sekine and Tadashi Matsuda

Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

1. Introduction

A number of molecular markers have recently been identified that may have prognostic value in breast cancer, and among the most notable of these are the estrogen receptor (ER) and the progesterone receptor (PR). ER/PR-positive breast cancer patients (60–80%) are hormone-responsive and therefore have a significantly better prognosis compared with ER/PR-negative patients (Clark and McGuire, 1983; Early Breast Cancer Trialists' Collaborative Group, 2005; Thorpe, 1988). However, approximately 50% of patients with advanced disease do not respond to endocrine therapy (Normanno et al., 2005).

Another well-known prognostic marker is epidermal growth factor receptor-2 (ErbB2; also known as HER2), which is a member of the epidermal growth factor receptor (EGFR) family. In approximately 30% of human breast cancers, ErbB2 is present at levels significantly above those found in normal cells (Hynes and Stern, 1994; Stern, 2000; Yarden, 2001). Recent studies have indicated that ErbB2 plays important roles in malignant transformation and tumorigenesis (Hudziak et al., 1987; Slamon et al., 1987, 1989). Therefore, breast cancer tumors that involve large amounts of ErbB2 protein are correlated with poor clinical outcomes (Menard et al., 2001). Herceptin (also known as Trastuzumab), a humanized monoclonal antibody against the extracellular domain of ErbB2, is used to treat patients expressing high levels of ErbB2. Although Herceptin significantly decreases the rates of breast cancer recurrence and mortality (Piccart-Gebhart et al., 2005; Slamon et al., 2001; Ward et al., 2009), almost 50% of patients with the ErbB2-amplified tumors do not respond to this treatment and develop resistance to the drug (Slamon et al., 2006).

Conversely, tumors with neither hormone receptor expression nor ErbB2 amplification are classified as triple-negative (TN) tumors (Sorlie et al., 2003). TN tumors are an aggressive subtype of breast cancer that account for approximately 15% of breast cancer cases. The TN tumor shows a higher histologic grade, and a worse prognosis compared with that of hormone receptor-positive or ErbB2-positive tumors (Dent et al., 2007; Liedtke et al., 2008). Therapeutically, despite being highly chemosensitive, their progression-free time is generally short (Dent et al., 2007; Liedtke et al., 2008), and TN tumors develop resistance to endocrine therapy and Herceptin, illustrating the urgent need for novel therapeutic strategies. Recently, new potential therapeutic targets for this type of breast cancer have been discovered, including poly-(ADP-ribose)-polymerase 1.
STAP-2 is a recently identified adaptor protein, which contains pleckstrin homology (PH) and src homology 2 (SH2)-like domains, as well as a signal transducer and activator of transcription 3 (STAT3)-binding motif in its C-terminal region (Minoguchi et al., 2003). Importantly, human STAP-2 was originally identified as BKS and is a substrate for BRK, a non-receptor protein tyrosine kinase (PTK) known alternatively as protein tyrosine kinase 6 (PTK6) (Mitchell et al., 2000). BRK is highly expressed in human breast cancer cells (Barker et al., 1997). Recently, STAP-2, STAT3, and STAT5A/B have been identified as BRK substrates. However, the molecular mechanism by which the STAP-2-BRK-STAT3/5 axis participates in the tumorigenesis in breast cancer remains poorly characterized. In this review, we focus on the STAP-2-BRK-STAT3/5 axis as a potential therapeutic target and/or prognostic marker and demonstrate a functional link between STAP-2 and BRK/STAT3/5-mediated transcriptional activation and cell growth in human breast cancer cells.

2. STAP-2

2.1 Structure and expression

Human STAP-2 is the first identified substrate for the BRK non-receptor tyrosine kinase (Mitchell et al., 2000). We also cloned murine STAP-2 as a c-fms interacting protein (Minoguchi et al., 2003). PTKs play an important role in regulating cell growth, differentiation, and transformation. Activated receptor tyrosine kinases trans-phosphorylate several tyrosines in their cytoplasmic domains, providing recognition sites for various adaptor and effector proteins in multiple signal transduction pathways. Adaptor proteins often function as inter- or intra-molecular bridges and thereby play an important role in the assembly of larger protein complexes or in the stabilization of certain conformational states. They also utilize their functional domains, such as SH2 and SH3 domains, to mediate interactions that link various proteins involved in signal transduction.

STAP-1 was cloned as a c-kit-interacting protein and bears high sequence and structural similarity to its sister protein, STAP-2 (Masuhara et al., 2000) (Fig. 1A). Both STAP-1 and STAP-2 contain an N-terminal PH domain and a region weakly related to an SH2 domain (overall 33% amino acid identity). The N-terminal PH domains of the STAP proteins share 36% amino acid identity and 58% similarity. In the absence of stimulation, over-expressed STAP-2 protein localizes throughout the cytoplasm and nucleus in A431 epidermoid carcinoma cells, but translocates to the plasma membrane following stimulation of EGFR. A mutant STAP-2 lacking the N-terminal PH domain (ΔPH) fails to localize at the plasma membrane, demonstrating that the PH domain of STAP-2 is necessary and sufficient for plasma membrane recruitment by EGFR stimulation.

The central region of STAP-2 is distantly related to the SH2 domain. This region of STAP-2 shares 40% sequence identity with that of STAP-1 and 29% sequence identity with the SH2 domain of human phospholipase C-γ2. However, STAP-2 has a C-terminal proline-rich
Interactions of STAP-2 with BRK and STAT3/5 in Breast Cancer Cells

Fig. 1. Schematic diagrams of the domain structures of the STAP-1 (A), STAP-2 (A, B), STAT3 (C), BRK and the STAP-2 PH-BRK fusion protein (D).

region and a STAT3-binding motif, YXXQ, both of which are absent from STAP-1. Cytokine receptors commonly utilize a YXXQ motif in their cytoplasmic regions to recruit and activate STAT3 (Hirano et al., 2000). STAP-2 is expressed in a variety of tissues and cells such as lymphocytes, macrophages and hepatocytes (Minoguchi et al., 2003), and its abundant expression pattern (Fig. 2A) suggests that STAP-2 influences a variety of signaling or transcriptional molecules. STAP-1, however, shows a more restricted expression pattern, being located predominantly in hematopoietic cells (Masuhara et al., 2000). Notably, STAP-2 is constitutively expressed in macrophages, and the 5' region of the STAP-2 genomic sequence contains several potential binding sites for c-Rel, AP-1, p65/NF-κB and STATs. In the murine myeloid leukemia cell line, M1, STAP-2 mRNA expression is strongly induced by LIF in parallel with its differentiation into macrophages. These expression patterns of STAP-2 support a paradigm whereby STAP-2 in macrophages mediates signals for acute-phase responses after infection. Indeed, LPS- or IL-6-stimulated induction of acute phase protein genes was significantly decreased in STAP-2-deficient hepatocytes (Minoguchi et al., 2003).
2.2 Interacting proteins

Recently, many STAP-2 binding partners have been identified. As summarized in Table 1, STAP-2 interacts with, and modulates the function of, several signaling molecules including STAT3/5 (Minoguchi et al., 2003; Sekine et al., 2005), FcεRI (Yamamoto et al., 2003), M-CSFR/c-FMS (Ikeda et al., 2007) and Toll-like receptor-mediated signals (Sekine et al., 2006). STAP-2 interacts with STAT3 through the C-terminal YXXQ motif and enhances STAT3 transcriptional activity. STAP-2 also interacts with STAT5 through its PH and SH2-like domains. It is noteworthy that thymocytes and peripheral T cells from STAP-2-deficient mice show enhanced IL-2- or TCR-dependent cell growth (Sekine et al., 2005). STAP-2 positively regulates LPS/TLR4-mediated signals in macrophages. STAP-2, particularly its SH2-like domain, binds to both MyD88 and IKK-α/β, but not to TRAF6 or IRAK1, and
forms a functional complex composed of MyD88-STAP-2-IKK-α/β. These interactions augment MyD88- and/or IKK-α/β-dependent signals, leading to enhancement of NF-κB activity (Sekine et al., 2006).

Table 1. STAP-2 interacting proteins.

| Interacting protein | Domain or region                  | References                                      |
|---------------------|-----------------------------------|------------------------------------------------|
| BRK                 | PH, (SH2-like)                    | Ikeda et al., 2009, 2010, 2011; Mitchel et al., 2000 |
| STAT3               | YXXQ motif, (SH2-like)            | Ikeda et al., 2010; Minoguchi et al., 2003     |
| STAT5A/B            | PH, SH2-like                      | Sekine et al., 2005                            |
| c-Fms               | PH, (SH2-like)                    | Sekine et al., 2007                            |
| PLCγ1/2             | SH2-like, C-terminal              | Yamamoto et al., 2003                          |
| MyD88               | SH2-like                          | Sekine et al., 2006                            |
| IKKα/β              | SH2-like                          | Sekine et al., 2006                            |
| LMP1                | PH, SH2-like                      | Ikeda et al., 2008                             |
| TRAF1               | Not determined                    | Ikeda et al., 2008                             |
| TRAF3               | PH, SH2-like                      | Ikeda et al., 2008                             |
| FAK                 | SH2-like                          | Sekine et al., 2007                            |
| Cbl                 | PH, SH2-like                      | Sekine et al., 2007                            |
| Vav1                | SH2-like, C-terminal              | Sekine et al., 2009                            |
| Rac1                | Not determined                    | Sekine et al., 2009                            |

M-CSFR/c-FMS directly interacts with the PH domain of STAP-2 independently following M-CSF-stimulation (Ikeda et al., 2007). STAP-2 regulates M-CSF-induced tyrosine phosphorylation of M-CSFR/c-FMS as well as the activation of Akt and extracellular signal regulated kinase. In addition, over-expression of STAP-2 results in the impairment of migration in response to M-CSF and of the wound-healing process in macrophages. This demonstrates that STAP-2 directly binds to M-CSFR/c-FMS and interferes with PI3K signaling, leading to macrophage motility. In T cells, STAP-2 enhances Cbl-dependent degradation of FAK and downregulates integrin/FAK-mediated cell adhesion to fibronectin (Sekine et al., 2007). Furthermore, STAP-2 constitutively interacts with, and enhances the tyrosine phosphorylation of, a GDP/GTP exchange factor, Vav1, and also binds to a small GTPase, Rac1 (Sekine et al., 2009). These interactions control chemokine-induced chemotaxis of T cells.

STAP-2 also interacts with Epstein-Barr virus (EBV)-derived latent membrane protein 1 (LMP1) and negatively regulates LMP1-induced NF-κB activation (Ikeda et al., 2008). EBV is linked to the development of multiple malignancies, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma (Thorley-Lawson, 2001). EBV-LMP1 is expressed in many EBV-associated tumor cells and is responsible for most of their altered cellular growth properties (Brinkmann and Schulz, 2006). STAP-2 associates with LMP1 through the PH and SH-2-like domains, and this interaction occurs physiologically in EBV-positive human B cells. STAP-2 regulates LMP1-mediated NF-κB signaling through direct or indirect interactions with TRAF3 and TRADD. Importantly, STAP-2 mRNA is induced by expression of LMP1 in human B cells, and transient expression of STAP-2 in EBV-positive human B cells decreases cell growth. These data suggest that STAP-2 responds to EBV infection and acts as an endogenous negative regulator of EBV-LMP1-mediated signaling through TRAF3 and TRADD.
3. BRK

3.1 Structure and expression

BRK was originally isolated from a metastatic breast carcinoma (Mitchell et al., 1994). An identical protein was independently cloned as a highly-expressed protein tyrosine kinase, PTK6, from human melanocytes (Lee et al., 1993). In addition, Ptk6 (previously termed Sik), a cDNA for the mouse ortholog that has 80% amino acid identity to BRK/PTK6, was also cloned from mouse intestinal crypt cells (Siyanova et al., 1994). BRK displays approximately 56% homology to the kinase domain of c-Src and a similar domain arrangement (Serfas and Tyner, 2003). BRK is a 451 amino acid protein that contains an SH3 domain, an SH2 domain and a tyrosine kinase catalytic domain, but lacks an N-terminal myristoylation site for membrane targeting (Serfas and Tyner, 2003). BRK is expressed in many malignancies, such as colon and prostate tumors and metastatic melanomas (Derry et al., 2003; Easty et al., 1997; Llor et al., 1999; Schmandt et al., 2006). BRK expression is also detected in a large proportion of human mammary gland tumors, but is not expressed in normal mammary gland (Barker et al., 1997). In normal tissues, BRK expression is developmentally regulated and restricted to differentiating epithelial cells in a range of tissues including small intestine and colon (Vasioukhin et al., 1995; Haegelbarth et al., 2005, 2006) (Fig. 2B).

3.2 Substrates, interacting proteins and activation

Several BRK-interacting proteins or substrates have been identified (Table 2). BRK substrates include RNA-binding proteins (Sam68 (Coyle et al., 2003; Derry et al., 2000; Lukong et al., 2005), SLM-1/2 (Haegelbarth et al., 2004), and the polypyrimidine tract-binding protein-associated splicing factor (PSF) (Lukong et al., 2009)), transcription factors (STAT3 (Liu et al., 2006) and STAT5A/B (Weaver and Silva, 2007)), adaptor molecules (STAP-2) (Mitchell et al., 2000), and a variety of signaling molecules (paxillin (Chen et al., 2004), p190RhoGAP (Shen et al., 2008), kinesin-associated protein 3A (KAP3A) (Lukong and Richard, 2008), Akt (Zhang et al., 2005), β-catenin (Palka-Hamblin et al., 2010), and ARAP1 (Arf-GAP, Rho-GAP, ankyrin repeat and PH domain-containing protein 1; also known as centaurin δ-2) (Kang et al., 2010)). Although BRK expression is known to induce tyrosine phosphorylation in some of these, similar actions in others have yet to be confirmed.

Sam68 is the most extensively studied BRK substrate. BRK expression suppressed cell proliferation through EGFR-mediated phosphorylation of Sam68 in a human breast cancer cell line (Coyle et al., 2003; Derry et al., 2000; Lukong et al., 2005). Similarly, BRK phosphorylates the Sam68-like mammalian proteins, SLM-1 and SLM-2, and negatively regulates their RNA-binding functions (Haegelbarth et al., 2004). Downstream of EGFR, PSF is a BRK substrate, and this tyrosine phosphorylation of PSF induces cytoplasmic relocalization, impairment of its binding to polypyrimidine RNA, and cell cycle arrest (Lukong et al., 2009). Furthermore, BRK expression promotes cell migration and tumor invasion by phosphorylating the focal adhesion protein, paxillin, followed by activation of the small GTPase, Rac1, via the function of CrkII (Chen et al., 2004). BRK also phosphorylates p190RhoGAP-A (regulating the small GTPases, RhoA and Ras, and promoting breast malignancy) (Shen et al., 2008); a kinesin-2 subunit, KAP3A (promoting cell migration) (Lukong and Richard, 2008); and Akt (regulating basal Akt activity in normal cells) (Zhang et al., 2005).
Table 2. BRK substrates.

| Substrate | Function | Phosphorylation site | References |
|-----------|----------|----------------------|------------|
| SAML1     | Cell cycle | Y345, Y434, Y440       | Coyle et al., 2003; Derry et al., 2000; Lukong et al., 2005 |
| SLM-1/SLM-2 | Not validated | Not determined       | Haagabarth et al., 2004 |
| PSF       | Cell cycle | C-terminus           | Lukong et al., 2009 |
| STAT3     | Cell cycle | Y705                 | Liu et al., 2006 |
| STAT5A/B  | Cell cycle | Y894/Y899            | Weaver and Silva, 2007 |
| STAP-2/BKS | Cell growth | Y250                 | Ikeda et al., 2009; Mitchel et al., 2006 |
| Paxillin  | Migration | Y91, Y118             | Chen et al., 2004 |
| p190RhoGAP | Migration | Y1109                | Shen et al., 2008 |
| KAP9A     | Migration | C-terminus           | Lukong and Richard, 2008 |
| Akt       | Intestinal epithelial cell differentiation | Not determined | Zhang et al., 2005 |
| beta-catenin | Cell growth | Y64, Y142, Y331, Y333 | Palka-Hamblin et al., 2010 |
| ARAP1/centaurin-2 | Regulation of EGFR internalization | Y231 | Kang et al., 2010 |
| BRK       | Regulation of kinase activity | Y13, Y61, Y66, Y114, Y342, Y351 | Qiu and Miller, 2002 |

Mice deficient in the BRK murine ortholog, Sik, show increased cell proliferation, decreased apoptosis, and increased levels of activated Akt in the small intestine (Haegebarth et al., 2006), suggesting a role for BRK in differentiation of epithelial cells of the small intestine. This is further implied by the evidence that BRK directly phosphorylates and inhibits β-catenin, interrupting T-cell factor-mediated transcription in the intestine, and indicating that BRK may be a negative regulator of the Wnt-signaling pathway (Palka-Hamblin et al., 2010).

BRK may contribute to tumorigenesis by modulating EGF/EGFR signaling. It phosphorylates ARAP1, which results sequentially in inhibition of EGFR internalization, increased duration of EGF/EGFR signaling, and increased oncogenic capacity (Kang et al., 2010). Importantly, over-expression of BRK sensitizes human mammary epithelial cells to EGF and/or heregulin stimuli, and increases anchorage-independent growth (Kamalati et al., 1996, 2000), while down-regulation of BRK also influences EGF- and heregulin-induced cell proliferation. These observations suggest that BRK is involved in signaling induced by members of the EGFR family (Ostrander et al., 2007). Notably, BRK interacts with additional ErbB family members (ErbB2, ErbB3, and ErbB4) as well as EGFR (ErbB1) (Kamalati et al., 1996; Aubele et al., 2007; Xiang et al., 2008). BRK is co-amplified with ErbB2 to promote proliferation and confer resistance to lapatinib, an ErbB2 kinase inhibitor in breast cancer (Xiang et al., 2008), suggesting that BRK is a potential target in ErbB2-positive breast cancer.

As mentioned above, BRK kinase activity is promoted by ligands for the ErbB receptor, such as EGF and heregulin. However, it is also activated by the expression of ErbB2 even in the absence of ligands, and by other stimuli such as IGF-1 (Qiu et al., 2005), calcium and ionomycin (Vasioukhin and Tyner, 1997; Wang et al., 2005), fetal bovine serum (Zhang et al., 2005), and osteopontin (Chakraborty et al., 2008). BRK activation occurs under the conditions already described, but also during keratinocyte differentiation, together with upregulation of expression (Wang et al., 2005).

The mechanism of regulation of BRK kinase activity is similar to SRC family kinases, with some notable differences. Structural studies reveal that BRK is autophosphorylated at Tyr-13, 61, 66, 114, 351 and 342 (Qiu and Miller, 2002). Tyr-342 (Y342 in BRK and Y416 in SRC) resides within the kinase activation loop, and phosphorylation of this residue increases kinase activity of wild-type (WT) BRK. However, mutation of Tyr-342 to alanine (Y342A) blocks activation of BRK (Qiu and Miller, 2002). In addition, mutation of the C-terminal
residue Tyr-447 (Y447 in BRK and Y527 in SRC) to Phe (Y447F) results in a constitutively active kinase (Kamalati et al., 1996). Trp-184 (W184 in BRK and W260 in SRC) lies within the SH2-kinase linker region and, in contrast to SRC family enzymes, has been shown to interact intramolecularly with residues in the BRK kinase domain. The conserved Trp184 to Ala (W184A) mutation completely inhibits kinase activity (Kim and Lee, 2005), as does the substitution of Lys-219 (K219 in BRK and K295 in SRC) with Met (K219M), which destroys the putative ATP binding site of BRK (Kamalati et al., 1996).

Unlike SRC family kinases, BRK lacks myristoylation signals for membrane targeting, allowing it some freedom in its subcellular localization and broadening its range of substrates and interacting proteins. Several studies demonstrate that the function of BRK varies between cell types and may be dependent on expression levels, kinase activity, interaction with substrates or other binding proteins and, significantly, on intracellular localization. Indeed, oncogenic functions of BRK are enhanced by targeting it to the plasma membrane but are abolished if it is modified to remain in the nucleus (Le Kim and Lee, 2009). BRK expression is detected in both the cytoplasm and nucleus in the normal intestine, skin and oral epithelium, and in breast and colon tumors (Brauer and Tyner, 2010). In normal differentiated prostate epithelium and in well-differentiated prostate tumors, it is detected in the nucleus, but is absent from the nuclei of poorly-differentiated tumors, which may implicate it in differentiation of the prostate (Derry et al., 2003). At the present time, it is not clear how intracellular localization of BRK is regulated. Therefore, further studies are required to confirm the significance of BRK subcellular localization. Indeed, BRK does not contain any nuclear localization or export signal, suggesting that interaction with substrates such as STAP-2 or other interacting proteins may be important in regulating its distribution.

4. Signal transducer and activator of transcription (STAT) 3/5

The signal transducer and activator of transcription (STAT) family is known to mediate cell proliferation, differentiation and survival in immune responses, hematopoiesis, neurogenesis and many other biological processes (Darnell et al., 1994; Ihle, 1996; O'Shea, 1997). Seven different STAT genes have currently been identified in mammals. The encoded proteins vary in length between 750–850 amino acid residues and share 20–50% amino acid sequence identity. As shown in Fig. 1, notable features of STAT proteins are the STAT family DNA binding domain, an SH2 domain and a major tyrosine phosphorylation site at Y705 (STAT3). In general, STAT proteins bind as dimers to DNA target sites with a nine-base-pair (bp) consensus sequence, TTCCGGGAA, and binding constants in the nanomolar range. In unstimulated cells, STATs are present as monomers in the cytoplasm. STATs are activated by phosphorylation at tyrosine residues, which leads to the formation of dimers via reciprocal interactions between the SH2 domain of one monomer and the phosphorylated tyrosine of the other. Dimers then translocate to the nucleus where they recognize specific DNA-binding sites and induce target gene transcription. Tyrosine phosphorylation of STATs (Y705 in STAT3, and Y694/Y699 in STAT5A/B, respectively) is normally a transient and tightly regulated process. However, in tumor cells, constitutive activation of STATs is linked to persistent activity of tyrosine kinases, including Janus kinases, Src, EGFR, Bcr-Abl, and many others. These kinases might be activated by cytokines or by structural alterations. For instance, EGFR over-expression and activation may underlie STAT activation in breast, lung and head and neck cancer (Zhang et al., 2004). Constitutive activation or dysregulated expression of STATs is detected in primary tumors and cancer
5. Interactions of STAP-2 with BRK and STAT3/5

5.1 BRK, STAP-2 and STAT3/5

STAP-2 is the first BRK interacting protein identified and shown to be phosphorylated. STAT3 and STAT5, which play crucial roles in cell proliferation and differentiation, are also believed to be activated by BRK (Liu et al., 2006; Weaver and Silva, 2007). Our previous studies demonstrate that STAP-2 interacts with and influences several signaling molecules, including STAT3 and STAT5. Furthermore, both STATs play fundamental roles in the normal growth and development of the mammary gland (Hennighausen et al., 1997), and are often over-expressed or constitutively-activated in breast cancer tumors (Bowman et al., 2000). It is therefore of key importance to clarify the interactions between BRK, STAP-2, and STAT3/5.

5.2 STAT3/5 activation by BRK and STAP-2

We attempted to elucidate the roles of STAP-2 in BRK-mediated transcriptional activation of STAT3/5 in breast cancer cells. Transient transfection experiments using expression of luciferase (Luc) reporter genes driven by STAT3 (STAT3-Luc) and STAT5 (STAT5-Luc) showed that STAP-2 enhances BRK-mediated activation of STAT3 and STAT5. We showed that co-expression of STAP-2 and BRK increases BRK-mediated STAT3/5 activation compared with BRK expression alone, and small-interfering RNA or short-hairpin RNA-mediated reduction of endogenous STAP-2 expression strongly decreases BRK-mediated STAT3/5 activation in T47D human breast cancer cells. To further clarify the molecular mechanisms underlying BRK/STAP-2-mediated STAT3/5 activation in breast cancer cells, we tested the effect of STAP-2 on BRK-mediated phosphorylation of STAT3/5, which is an important step for transcriptional activation. Phosphorylation of STAT3/5 is markedly enhanced in MCF7 human breast cancer cells overexpressing STAP-2. In addition, constitutive phosphorylation of STAT3/5 in control T47D cells is markedly reduced in STAP-2 knockdown cell clones. These results indicate that STAP-2 plays important roles in BRK-mediated tyrosine phosphorylation of STAT3/5 in breast cancer cells.

5.3 Molecular interactions among STAP-2, STAT3, STAT5 and BRK

We previously reported that STAP-2 binds to several functional molecules. For example, the SH2 domain of STAP-2 interacts with MyD88 and IKKs (Sekine et al., 2006), and the PH and SH2 domains of STAP-2 mediate its association with STAT5 (Sekine et al., 2005), LMP1 and TRAF3 (Ikeda et al., 2008). To assess the functional relationships among BRK, STAP-2 and STAT3/5, we determined the domains of STAP-2 responsible for BRK-mediated STAT3/5 activation. The BRK-mediated STAT3/5-Luc activity is significantly and dose-dependently enhanced by expression of STAP-2 WT and, to a slightly lesser degree, by expression of the mutant STAP-2 ΔSH2 and STAP-2 ΔC genes, which lack the SH2 domain and the C-terminal domain, respectively. Importantly, however, STAP-2 ΔPH (lacking the PH domain) does not elevate STAT3/5-Luc activity mediated by BRK. Similarly, enhanced phosphorylation of
STAT3/5 by BRK is observed in the presence of a construct encoding just the STAP-2 PH domain (STAP-2 PH). These findings indicate that the PH domain of STAP-2 plays an essential role in the BRK-mediated STAT3/5 activation. However, BRK-mediated STAT3/5 phosphorylation is incomplete in the presence of the STAP-2 PH domain compared to that induced by STAP-2 WT, indicating that other domains of STAP-2 may be required for full BRK-mediated STAT3/5 phosphorylation.

5.4 BRK kinase activity and intracellular localization
Aside from differences in phosphorylation profiles, further differences between STAP-2 WT and STAP-2 ΔPH were confirmed with confocal microscopy experiments. STAP-2 WT is distributed throughout the cytoplasm and nucleus, but STAP-2 ΔPH is located mainly in the cytoplasm. Interestingly, BRK distribution is largely consistent with that of STAP-2, being localized in the nucleus only in the presence of STAP-2 WT, and localizing entirely in the cytoplasm when the PH domain of STAP-2 is disrupted (i.e. in the presence of STAP-2 ΔPH). From this, we can conclude that STAP-2, via its PH domain, affects BRK distribution, probably because of its effects on the activation state of BRK. To clarify the effect of the STAP-2 PH domain on BRK activation, we used a STAP-2 PH-BRK fusion protein (PH-BRK), in which BRK is fused to the N terminus of STAP-2 PH. PH-BRK shows robust kinase activity compared with BRK WT and induces marked activation and tyrosine phosphorylation of STAT3 in breast cancer cells. Moreover, PH-BRK is mainly localized in the nucleus, although BRK is localized throughout the cytoplasm and nucleus. Therefore, the STAP-2 PH domain controls the kinase activity and localization of BRK and thus regulates BRK-mediated STAT3 activation. Similarly, PH-BRK also activates STAT5 (data not shown).

5.5 Cell growth
STAP-2 knockdown T47D clones grow more slowly than control T47D cells. Reducing the expression of BRK, STAT3, STAT5b, or STAP-2 expression in T47D cells using siRNA causes a significant decrease in cell growth, indicating that these proteins play important roles in T47D cell growth. It is noteworthy that growth is decreased to similar extents in these four T47D cell types. This may suggest that BRK-induced cell growth in T47D cells is largely dependent on STAT3/5 and STAP-2. Notably, the expression of several genes in the STAT3/5-mediated signaling pathway, including SOCS3, C/EBPδ, cyclin D1, and c-Myc, is also reduced by STAP-2 knockdown in T47D cells. Taken together, BRKSTAT3/5-mediated proliferation is a major mechanism for breast cancer cell growth, and STAP-2 plays essential roles in this process.

6. Conclusion
Activation of STAT3/5 by BRK is a critical event during the process of BRK-mediated tumorigenesis in breast cancer cells. Our manipulation of STAP-2 expression revealed essential roles of STAP-2 in this process through complex interactions between BRK, STAP-2 and STAT3/5. In particular, experiments using deletion mutants indicated that the PH domain of STAP-2 is involved in multiple processes including binding between BRK and STAP-2, activation and phosphorylation of STAT3/5, and activation of BRK. These findings suggest a model for how STAP-2 cooperates with BRK to enhance breast cancer growth. Our proposed mechanisms are now illustrated in Fig. 3. Taken together, STAP-2 plays crucial
Fig. 3. Schematic showing the proposed function of STAP-2 in BRK-mediated STAT signaling. STAT activation occurs as shown via growth factor receptor signaling (EGFR), or nonreceptor tyrosine kinase signaling (BRK). BRK is not required when STATs bind directly to EGFR for activation (upper left), but BRK enhances activation of STATs phosphorylated by EGFR-activated BRK (upper right). In this pathway, STAP-2 can form complex with BRK and STAT, leading to activation of both BRK and STAT. Once activated, STATs dimerize and translocate to the nucleus where they activate the transcription of genes involved in proliferation, survival, and differentiation.
roles in both the BRK/STAT3 and BRK/STAT5 axes, which are major events for BRK-induced breast cancers. Our findings regarding BRK/STAP-2 interactions will therefore be helpful in developing breast cancer treatments. Furthermore, the synergistic effects of BRK and STAP-2 on STAT3/5 activation suggest that evaluating the expression of BRK together with STAP-2 may provide more useful prognostic scores for the outcomes of breast carcinomas than by measuring BRK expression alone.

7. References
Aubele, M., Auer, G., Walch, A.K., Munro, A., Atkinson, M.J., Braselmann, H., Fornander, T., and Bartlett, J.M. (2007). PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer, 96, 801-807.

Aubele, M., Walch, A.K., Ludyga, N., Braselmann, H., Atkinson, M.J., Luber, B., Auer, G., Tapio, S., Cooke, T., and Bartlett, J.M. (2008). Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br J Cancer, 99, 1089-1095.

Barker, K.T., Jackson, L.E., and Crompton, M.R. (1997). BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene, 15, 799-805.

Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000). STATs in oncogenesis. Oncogene, 19, 2474-2488.

Brauer, P.M., and Tyner, A.L. (2010). Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta, 1806, 66-73.

Brinkmann, M.M., and Schulz, T.F. (2006). Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J Gen Virol, 87, 1047-1074.

Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Hellday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913-917.

Caldas-Lopes, E., Cerchietti, L., Ahn, J.H., Clement, C.C., Robles, A.I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., Wu, N., de Stanchina, E., White, J., Gross, S.S., Ma, Y., Varticovski, L., Melnick, A., and Chiosis, G. (2009). Hsp90 inhibitor PH-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A, 106, 8368-8373.

Chakraborty, G., Jain, S., and Kundu, G.C. (2008). Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res, 68, 152-161.

Chen, H.Y., Shen, C.H., Tsai, Y.T., Lin, F.C., Huang, Y.P., and Chen, R.H. (2004). Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol, 24, 10558-10572.

Clark, G.M., and McGuire, W.L. (1983). Prognostic factors in primary breast cancer. Breast Cancer Res Treat, 3 Suppl, S69-72.

Conlin, A.K., and Seidman, A.D. (2008). Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. Clin Breast Cancer, 8, 215-223.
Corkery, B., Crown, J., Clynes, M., and O'Donovan, N. (2009). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. *Ann Oncol*, 20, 862-867.

Coyle, J.H., Guzik, B.W., Bor, Y.C., Jin, L., Eisner-Smerage, L., Taylor, S.J., Rekosh, D., and Hammerskjold, M.L. (2003). Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK. *Mol Cell Biol*, 23, 92-103.

Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science*, 264, 1415-1421.

Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., Lickley, L.A., Rawlinson, E., Sun, P., and Narod, S.A. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 13, 4429-4434.

Derry, J.J., Prins, G.S., Ray, V., and Tyner, A.L. (2003). Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. *Oncogene*, 22, 4212-4220.

Derry, J.J., Richard, S., Valderrama Carvajal, H., Ye, X., Vasioukhin, V., Cochrane, A.W., Chen, T., and Tyner, A.L. (2000). Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. *Mol Cell Biol*, 20, 6114-6126.

Desrivieres, S., Kunz, C., Barash, I., Vafaizadeh, V., Borghouts, C., and Groner, B. (2006). The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. *J Mammary Gland Biol Neoplasia*, 11, 75-87.

Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*, 365, 1687-1717.

Easty, D.J., Mitchell, P.J., Patel, K., Florenes, V.A., Spritz, R.A., and Bennett, D.C. (1997). Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. *Int J Cancer*, 71, 1061-1065.

Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P.W., Holstege, H., Liu, X., van Drunen, E., Beverloo, H.B., Smith, G.C., Martin, N.M., Lau, A., O'Connor, M.J., and Jonkers, J. (2008). Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. *Clin Cancer Res*, 14, 3916-3925.

Finn, R.S., Dering, J., Ginther, C., Wilson, C.A., Glaspy, P., Tekemlyedian, N., Slamov, D.J. (2007). Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. *Breast Cancer Res Treat*, 105:319-26.

Haegebarth, A., Bie, W., Yang, R., Crawford, S.E., Vasioukhin, V., Fuchs, E., and Tyner, A.L. (2006). Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. *Mol Cell Biol*, 26, 4949-4957.

Haegebarth, A., Heap, D., Bie, W., Derry, J.J., Richard, S., and Tyner, A.L. (2004). The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. *J Biol Chem*, 279, 54398-54404.
Haegebarth, A., Nunez, R., and Tyner, A.L. (2005). The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. *Cell Cycle*, 4, 1239-1246.

Hennighausen, L., Robinson, G.W., Wagner, K.U., and Liu, X. (1997). Developing a mammary gland is a stat affair. *J Mammary Gland Biol Neoplasia*, 2, 365-372.

Hirano, T., Ishihara, K., and Hibi, M. (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. *Oncoogene*, 19, 2548-2556.

Hudziak, R.M., Schlessinger, J., and Ullrich, A. (1987). Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc Natl Acad Sci U S A*, 84, 7159-7163.

Hynes, N.E., and Stern, D.F. (1994). The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta*, 1198, 165-184.

Ie Kim, H., and Lee, S.T. (2009). Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. *J Biochem*, 146, 133-139.

Ihle, J.N. (1996). STATs and MAPKs: obligate or opportunistic partners in signaling. *Bioessays*, 18, 95-98.

Ikeda, O., Miyasaka, Y., Sekine, Y., Mizushima, A., Muromoto, R., Nanbo, A., Yoshimura, A., and Matsuda, T. (2009). STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. *Biochem Biophys Res Commun*, 384, 71-75.

Ikeda, O., Mizushima, A., Sekine, Y., Yamamoto, C., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2011). Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. *Cancer Sci*, 102, 756-761.

Ikeda, O., Sekine, Y., Kakisaka, M., Tsuji, S., Muromoto, R., Ohbayashi, N., Oritani, K., Yoshimura, A., and Matsuda, T. (2007). STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells. *Biochem Biophys Res Commun*, 358, 931-937.

Ikeda, O., Sekine, Y., Mizushima, A., Nakasui, M., Miyasaka, Y., Yamamoto, C., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2010). Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. *J Biol Chem*, 285, 38093-38103.

Ikeda, O., Sekine, Y., Yasui, T., Oritani, K., Sugiyama, K., Muromoto, R., Ohbayashi, N., Yoshimura, A., and Matsuda, T. (2008). STAP-2 negatively regulates both canonical and noncanonical NF-kappaB activation induced by Epstein-Barr virus-derived latent membrane protein 1. *Mol Cell Biol*, 28, 5027-5042.

Kamalati, T., Jolin, H.E., Fry, M.J., and Crompton, M.R. (2000). Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. *Oncoogene*, 19, 5471-5476.

Kamalati, T., Jolin, H.E., Mitchell, P.J., Barker, K.T., Jackson, L.E., Dean, C.J., Page, M.J., Gusterson, B.A., and Crompton, M.R. (1996). Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. *J Biol Chem*, 271, 30956-30963.
Interactions of STAP-2 with BRK and STAT3/5 in Breast Cancer Cells

Kang, S.A., Lee, E.S., Yoon, H.Y., Randazzo, P.A., and Lee, S.T. (2010). PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1. J Biol Chem, 285, 26013-26021.

Kim, H., and Lee, S.T. (2005). An intramolecular interaction between SH2-kinase linker and kinase domain is essential for the catalytic activity of protein-tyrosine kinase-6. J Biol Chem, 280, 28973-28980.

Lee, S.T., Strunk, K.M., and Spritz, R.A. (1993). A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene, 8, 3403-3410.

Liedtke, C., Mazouni, C., Hess, K.R., Andre, F., Tordai, A., Mejia, J.A., Symmans, W.F., Gonzalez-Angulo, A.M., Hennessy, B., Green, M., et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-1281.

Liu, L., Gao, Y., Qiu, H., Miller, W.T., Poli, V., and Reich, N.C. (2006). Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene, 25, 4904-4912.

Llor, X., Serfas, M.S., Bie, W., Vasioukhin, V., Polonskaia, M., Derry, J., Abbott, C.M., and Tyner, A.L. (1999). BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 5, 1767-1777.

Lukong, K.E., Huot, M.E., and Richard, S. (2009). BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest. Cell Signal, 21, 1415-1422.

Lukong, K.E., Larocque, D., Tyner, A.L., and Richard, S. (2005). Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem, 280, 38639-38647.

Lukong, K.E., and Richard, S. (2008). Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. Cell Signal, 20, 432-442.

Masuhara, M., Nagao, K., Nishikawa, M., Sasaki, M., Yoshimura, A., and Osawa, M. (2000). Molecular cloning of murine STAP-1, the stem-cell-specific adaptor protein containing PH and SH2 domains. Biochem Biophys Res Commun, 268, 697-703.

Menard, S., Fortis, S., Castiglioni, F., Agresti, R., and Balsari, A. (2001). HER2 as a prognostic factor in breast cancer. Oncology, 61 Suppl 2, 67-72.

Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, I.J., Carver, J., Chan, E., Moss, K.G., Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G., and Cherrington, J.M. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9, 327-337.

Minoguchi, M., Minoguchi, S., Aki, D., Joo, A., Yamamoto, T., Yumioka, T., Matsuda, T., and Yoshimura, A. (2003). STAP-2/BKS, an adapter/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. J Biol Chem, 278, 11182-11189.

Mitchell, P.J., Barker, K.T., Martindale, J.E., Kamalati, T., Lowe, P.N., Page, M.J., Gusterson, B.A., and Crompton, M.R. (1994). Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene, 9, 2383-2390.

Mitchell, P.J., Sara, E.A., and Crompton, M.R. (2000). A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene, 19, 4273-4282.
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., De Matteis, A., Giordano, A., and Perrone, F. (2005). Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. *Endocr Relat Cancer, 12*, 721-747.

O'Shea, J.J. (1997). JakS, STATs, cytokine signal transduction, and immunoregulation: are we there yet? *Immunity*, 7, 1-11.

Ostrander, J.H., Daniel, A.R., Lofgren, K., Kleer, C.G., and Lange, C.A. (2007). Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. *Cancer Res, 67*, 4199-4209.

Pal, S.K., and Mortimer, J. (2009). Triple-negative breast cancer: novel therapies and new directions. *Maturitas*, 63, 269-274.

Palka-Hamblin, H.L., Gierut, J.J., Bie, W., Brauer, P.M., Zheng, Y., Asara, J.M., and Tyner, A.L. (2010). Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. *J Cell Sci*, 123, 236-245.

Petro, B.J., Tan, R.C., Tyner, A.L., Lingen, M.W., and Watanabe, K. (2004). Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. *Oral Oncol, 40*, 1040-1047.

Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, L., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C.H., Steger, G., Huang, C.S., Andersson, M., Inbar, M., Lichinitser, M., Láng, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T.M., Rüsshoff, J., Suto, T., Creatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M.S., and Gelber, R.D.; Herceptin Adjuvant (HERA) Trial Study Team. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med*, 353, 1659-1672.

Qiu, H., and Miller, W.T. (2002). Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. *J Biol Chem, 277*, 34634-34641.

Qiu, H., Zappacosta, F., Su, W., Annan, R.S., and Miller, W.T. (2005). Interaction between Brk kinase and insulin receptor substrate-4. *Oncogene, 24*, 5656-5664.

Saal, L.H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J.S., Malmstrom, P.O., Mansukhani, M., Enoksson, J., Hibshoosh, H., Borg, A., and Parsons, R. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res, 65*, 2554-2559.

Schmandt, R.E., Bennett, M., Clifford, S., Thornton, A., Jiang, F., Broaddus, R.R., Sun, C.C., Lu, K.H., Sood, A.K., and Gershenson, D.M. (2006). The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. *Cancer Biol Ther, 5*, 1136-1141.

Sekine, Y., Ikeda, O., Tsuji, S., Yamamoto, C., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2009). Signal-transducing adaptor protein-2 regulates stomal cell-derived factor-1 alpha-induced chemotaxis in T cells. *J Immunol, 183*, 7966-7974.

Sekine, Y., Tsuji, S., Ikeda, O., Sugiyama, K., Oritani, K., Shimoda, K., Muromoto, R., Ohbayashi, N., Yoshimura, A., and Matsuda, T. (2007). Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. *J Immunol, 179*, 2397-2407.
Sekine, Y., Yamamoto, C., Ikeda, O., Muromoto, R., Nanbo, A., Oritani, K., Yoshimura, A., and Matsuda, T. (2009). The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. Biochem Biophys Res Commun, 384, 187-192.

Sekine, Y., Yamamoto, T., Yumioka, T., Sugiyama, K., Tsuji, S., Oritani, K., Shimoda, K., Minoguchi, M., Yoshimura, A., and Matsuda, T. (2005). Physical and functional interactions between STAP-2/BKS and STAT5. J Biol Chem, 280, 8188-8196.

Sekine, Y., Yumioka, T., Yamamoto, T., Muromoto, R., Imoto, S., Sugiyama, K., Oritani, K., Shimoda, K., Minoguchi, M., Akira, S., Yoshimura, A., and Matsuda, T. (2006). Modulation of TLR4 signaling by a novel adaptor protein signal-transducing adaptor protein-2 in macrophages. J Immunol, 176, 380-389.

Serfas, M.S., and Tyner, A.L. (2003). Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res, 13, 409-419.

Shen, C.H., Chen, H.Y., Lin, M.S., Li, F.Y., Chang, C.C., Kuo, M.L., Settleman, J., and Chen, R.H. (2008). Breast tumor kinase phosphorylates p90RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res, 68, 7779-7787.

Siyanova, E.Y., Serfas, M.S., Mazo, I.A., and Tyner, A.L. (1994). Tyrosine kinase gene expression in the mouse small intestine. Oncogene, 9, 2053-2057.

Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.

Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.

Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-792.

Slamon, D.J., Romond, E.H., and Perez, E.A. (2006). Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol, 4, suppl 1, 4-9; discussion suppl 10; quiz 12 p following suppl 10.

Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C.M., Lenning, P.E., Brown, P.O., Berresen-Dale, A.L., and Botstein, D. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100, 8418-8423.

Stern, D.F. (2000). Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res, 2, 176-183.

Thorley-Lawson, D.A. (2001). Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 1, 75-82.

Thorpe, S.M. (1988). Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol, 27, 1-19.

Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., Wardley, A., Mitchell, G., Earl, H., Wickens, M., and Carmichael, J. (2010). Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, 376, 235-244.

Vasioukhin, V., Serfas, M.S., Siyanova, E.Y., Polonskaia, M., Costigan, V.J., Liu, B., Thomason, A., and Tyner, A.L. (1995). A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. *Oncogene*, 10, 349-357.

Vasioukhin, V., and Tyner, A.L. (1997). A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. *Proc Natl Acad Sci U S A*, 94, 14477-14482.

Wang, T.C., Jee, S.H., Tsai, T.F., Huang, Y.L., Tsai, W.L., and Chen, R.H. (2005). Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. *Br J Dermatol*, 153, 282-289.

Ward, S., Pilgrim, H., and Hind, D. (2009). Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. *Health Technol Assess*, 13 Suppl 1, 1-6.

Weaver, A.M., and Silva, C.M. (2007). Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. *Breast Cancer Res*, 9, R79.

Wang, T.C., Jee, S.H., Tsai, T.F., Huang, Y.L., Tsai, W.L., and Chen, R.H. (2005). Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. *Br J Dermatol*, 153, 282-289.

Ward, S., Pilgrim, H., and Hind, D. (2009). Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. *Health Technol Assess*, 13 Suppl 1, 1-6.

Weaver, A.M., and Silva, C.M. (2007). Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. *Breast Cancer Res*, 9, R79.

Wang, T.C., Jee, S.H., Tsai, T.F., Huang, Y.L., Tsai, W.L., and Chen, R.H. (2005). Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. *Br J Dermatol*, 153, 282-289.

Ward, S., Pilgrim, H., and Hind, D. (2009). Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. *Health Technol Assess*, 13 Suppl 1, 1-6.

Weaver, A.M., and Silva, C.M. (2007). Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. *Breast Cancer Res*, 9, R79.

Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W.T., and Muthuswamy, S.K. (2008). Brk is coamplified with ErbB2 to promote proliferation in breast cancer. *Proc Natl Acad Sci U S A*, 105, 12463-12468.

Yamamoto, T., Yumioka, T., Sekine, Y., Sato, N., Minoguchi, M., Yoshimura, A., and Matsuda, T. (2003). Regulation of FcepsilonRI-mediated signaling by an adaptor protein STAP-2/BSK in rat basophilic leukemia RBL-2H3 cells. *Biochem Biophys Res Commun*, 306, 767-773.

Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. *Oncology*, 61 Suppl 2, 1-13.

Zhang, P., Ostrander, J.H., Faivre, E.J., Olsen, A., Fitzsimmons, D., and Lange, C.A. (2005). Regulated association of protein kinase B/Akt with breast tumor kinase. *J Biol Chem*, 280, 1982-1991.

Zhang, Q., Thomas, S.M., Xi, S., Smithgall, T.E., Siegfried, J.M., Kamens, J., Gooding, W.E., and Grandis, J.R. (2004). SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. *Cancer Res*, 64, 6166-6173.
Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Osamu Ikeda, Yuichi Sekine and Tadashi Matsuda (2011). Interactions of STAP-2 with BRK and STAT3/5 in Breast Cancer Cells, Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, Prof. Mehmet Gunduz (Ed.), ISBN: 978-953-307-714-7, InTech, Available from: http://www.intechopen.com/books/breast-cancer-carcinogenesis-cell-growth-and-signalling-pathways/interactions-of-stap-2-with-brk-and-stat3-5-in-breast-cancer-cells
